

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**POST-EFFECTIVE AMENDMENT NO. 1 TO  
FORM S-1  
REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933**

---

**ONCOBIOLOGICS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**2836**  
(Primary Standard Industrial  
Classification Code Number)

---

**38-3982704**  
(I.R.S. Employer  
Identification No.)

**7 Clarke Drive  
Cranbury, New Jersey 08512  
(609) 619-3990**

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

---

**Lawrence A. Kenyon  
Chief Financial Officer  
Oncobiologics, Inc.  
7 Clarke Drive  
Cranbury, New Jersey 08512  
(609) 619-3990**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

---

**Copies to:  
Yvan-Claude J. Pierre  
Marianne C. Sarrazin  
Cooley LLP  
1114 Avenue of the Americas  
New York, New York 10036  
(212) 479-6000**

---

**Approximate date of commencement of proposed sale to the public: Not Applicable.**

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer       Accelerated filer       Non-accelerated filer       Smaller reporting company   
(Do not check if a smaller reporting company)      Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act.

---



## DEREGISTRATION OF SECURITIES

Oncobiologics, Inc. (the "**Company**") is filing this Post-Effective Amendment No. 1 to Registration Statement on Form S-1 to withdraw and remove from registration the unsold shares of the Company's common stock, \$0.01 par value per share, if any, previously registered for resale by the Company pursuant to the Registration Statement on Form S-1 (File No. 333-216080), originally filed with the SEC on February 15, 2017, (the "**Registration Statement**").

In accordance with an undertaking made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that had been registered for resale that remain unsold at the termination of the offering, the Company hereby removes from registration all of its securities registered but unsold under the Registration Statement as of the date hereof. The Company is deregistering such securities because it is no longer obligated to maintain the effectiveness of the Registration Statement.

---

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Post-Effective Amendment No. 1 to Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in Cranbury, New Jersey, on March 27, 2018.

### ONCOBIOLOGICS, INC.

By: /s/ Pankaj Mohan  
Pankaj Mohan, Ph.D.  
Chairman, President and Chief Executive Officer

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Pankaj Mohan, Ph.D. and Lawrence A. Kenyon and each of them, individually, as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead in any and all capacities, in connection with this registration statement, including to sign in the name and on behalf of the undersigned, this registration statement and any and all amendments thereto, including post-effective amendments and registrations filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto such attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
<u>/s/ Pankaj Mohan</u> Pankaj Mohan, Ph.D.	Chairman, President and Chief Executive Officer <i>(Principal Executive Officer)</i>	March 27, 2018
<u>/s/ Lawrence A. Kenyon</u> Lawrence A. Kenyon	Chief Financial Officer <i>(Principal Accounting and Financial Officer)</i>	March 27, 2018
<u>/s/ Claudio Albrecht</u> Claudio Albrecht, M.D., Ph.D.	Director	March 27, 2018
<u>/s/ Scott A. Canute</u> Scott A. Canute	Director	March 27, 2018
<u>/s/ Joerg Windisch</u> Joerg Windisch, Ph.D.	Director	March 27, 2018
<u>/s/ Kurt J. Hilzinger</u> Kurt J. Hilzinger	Director	March 27, 2018
<u>/s/ Faisal G. Sukhtian</u> Faisal G. Sukhtian	Director	March 27, 2018
<u>/s/ Joe Thomas</u> Joe Thomas	Director	March 27, 2018